You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer

Article metrics

Article menu

Download PDFPDF

XML
Immune cell therapies and immune cell engineering
Original research
Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer

 

Online download statistics by month:

Online download statistics by month: March 2020 to March 2024

AbstractFullPdf
Mar 202025325358
Apr 202010410441
May 2020848423
Jun 2020454517
Jul 2020656516
Aug 2020323210
Sep 2020727234
Oct 2020494923
Nov 2020434519
Dec 2020535314
Jan 2021515121
Feb 2021393911
Mar 2021717124
Apr 202128028021
May 2021515124
Jun 2021373724
Jul 2021595916
Aug 2021424219
Sep 2021494933
Oct 2021797955
Nov 2021737336
Dec 2021474717
Jan 2022545613
Feb 2022384224
Mar 2022465019
Apr 2022475311
May 2022636429
Jun 2022616331
Jul 2022566022
Aug 2022535322
Sep 2022475022
Oct 2022626323
Nov 2022505224
Dec 2022333324
Jan 202322237
Feb 2023555513
Mar 2023282917
Apr 2023242612
May 2023161817
Jun 2023343416
Jul 2023232312
Aug 2023424315
Sep 2023969610
Oct 202319919916
Nov 202334834815
Dec 202366669
Jan 2024343517
Feb 2024323211
Mar 2024353548
Total334233811055